EuroPCR 2024: Late-Breaking Science Video Collection
Published: 20 May 2024
-
Views:
1181
-
Likes:
7
-
Views:
1181
-
Likes:
7
-
Up Next -
5m 19sPart 1 | Session 3 Ancillary SMART Trial Analyses -
3m 59sPart 1 | Session 4 Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY -
4m 6s -
26m 48sPart 1 | Session 6 1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II
-
26m 3sPart 2 | Session 1 View from the Thoraxcenter: What's Hot at EuroPCR 24? -
18m 29sPart 2 | Session 2 View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1
-
4m 13sPart 3 | Session 1 5 Trials That Will Change My Practice With Dr Mirvat Alasnag -
6m 27sPart 3 | Session 2 4 Trials That Will Change My Practice with Dr Bernardo Cortese
-
4m 31sPart 1 | Session 1 Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Hans-Josef Feistritzer
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.
More from this programme
Part 1
Expert Interviews
Part 2
View from the Thoraxcenter
Part 3
Highlights Reviews
About the episode
EuroPCR 24 - We are joined onsite by Dr Carlos Collet (OLV Hospital Aalst, BE) to discuss the findings from a study analysing the influences of the pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI.
The study aimed to assess the capacity of pullback pressure gradient (PPG) in predicting post-PCI fractional flow ratio (FFR), as well as the impact of PPG on procedural outcomes. 982 stable patients with at least one hemodynamically significant lesion intended to be treated with percutaneous coronary intervention (PCI) were enrolled in the trial. Findings showed that PPG before PCI predicted post-PCI FFR, and periprocedural myocardial infarction was lower in focal disease as opposed to diffuse disease.
Interview Questions:
- What is the rationale behind this study?
- What is the patient population and study design?
- What are your key findings?
- What should be the impact of these findings on clinical practice?
- What further research is needed, and what are the next steps?
Recorded onsite at EuroPCR 2024, Paris.
Editor: Jordan Rance
Video Specialist: Dan Brent, Oliver Miles
Interviewer: Bryony Wickens
Faculty Biographies
Carlos Collet
Interventional Cardiologist
Dr Carlos Collet practices as an interventional cardiologist at Olv Hospital Aalst, Aalst, BE.
Dr Collet earned a doctorate in Cardiovascular Sciences from the University of Amsterdam. During his doctoral studies, he devoted his research to the integration of coronary imaging and physiology in patients with complex coronary artery disease.
He has published over 300 peer-reviewed articles and serves as the co-director of the catheterisation laboratory at the Cardiovascular Center OLV Aalst in Belgium.
Comments